Sunday, April 12, 2015 5:22:15 PM
On March 16th, the Company repurchased 44,145 shares of its common stock. The total amount of shares held by insiders and institutional investors as of March 17th is 3,447,779. Of this amount, 3,168,846 shares are held by insiders and 278,933 shares are held by institutional investors. The company has in place a program which allows it to repurchase up to 250,000 shares each year. Since January 1st, the company has repurchased 84,627 shares of its common stock.
As of December 31, 2014, the Company had net assets of $24,580,735 or $6.16 per share.
http://finance.yahoo.com/news/daxor-receives-notification-patent-approval-165824835.html
Recent DXR News
- New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™) • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 • GlobeNewswire Inc. • 03/22/2024 12:00:00 PM
- Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 • GlobeNewswire Inc. • 03/18/2024 06:18:00 PM
- Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders • GlobeNewswire Inc. • 03/18/2024 06:18:00 PM
- Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend] • Edgar (US Regulatory) • 03/08/2024 06:49:31 PM
- Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:18:32 PM
- Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend] • Edgar (US Regulatory) • 02/29/2024 10:28:32 PM
- Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report) • Edgar (US Regulatory) • 02/29/2024 09:15:19 PM
- Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:52:42 PM
- Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer • GlobeNewswire Inc. • 01/02/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 08:48:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 02:00:56 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM